ZLD1039
new
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406819

CAS#: 1826865-46-6

Description: ZLD1039 is a potent, highly selective, and orally bioavailable small molecule inhibitor of EZH2, which inhibited breast tumor growth and metastasis. ZLD1039 considerably inhibited EZH2 methyltransferase activity with nanomolar potency, decreased global histone-3 lysine-27 (H3K27) methylation, and reactivated silenced tumor suppressors connected to increased survival of patients with breast cancer. Comparable to conditional silencing of EZH2, its inhibition by ZLD1039 decreased cell proliferation, cell cycle arrest, and induced apoptosis. ZLD1039 is a promising treatment for breast cancer.


Chemical Structure

img
ZLD1039
CAS# 1826865-46-6

Theoretical Analysis

MedKoo Cat#: 406819
Name: ZLD1039
CAS#: 1826865-46-6
Chemical Formula: C36H48N6O3
Exact Mass: 612.38
Molecular Weight: 612.819
Elemental Analysis: C, 70.56; H, 7.90; N, 13.71; O, 7.83

Price and Availability

Size Price Availability Quantity
10mg USD 375
50mg USD 1110
Bulk inquiry

Synonym: ZLD1039; ZLD-1039; ZLD 1039.

IUPAC/Chemical Name: 3-[Ethyl(tetrahydro-2H-pyran-4-yl)amino]-N-[(2,3,5,6,7,8-hexahydro-1-methyl-3-oxo-4-isoquinolinyl)methyl]-2-methyl-5-[6-(4-methyl-1-piperazinyl)-3-pyridinyl]-benzamide

InChi Key: SZAYCVHJDOWSNY-UHFFFAOYSA-N

InChi Code: InChI=1S/C36H48N6O3/c1-5-42(28-12-18-45-19-13-28)33-21-27(26-10-11-34(37-22-26)41-16-14-40(4)15-17-41)20-31(24(33)2)35(43)38-23-32-30-9-7-6-8-29(30)25(3)39-36(32)44/h10-11,20-22,28H,5-9,12-19,23H2,1-4H3,(H,38,43)(H,39,44)

SMILES Code: O=C(NCC1=C2CCCCC2=C(C)NC1=O)C3=CC(C4=CC=C(N5CCN(C)CC5)N=C4)=CC(N(CC)C6CCOCC6)=C3C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 612.82 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Song X, Gao T, Wang N, Feng Q, You X, Ye T, Lei Q, Zhu Y, Xiong M, Xia Y, Yang
F, Shi Y, Wei Y, Zhang L, Yu L. Corrigendum: Selective inhibition of EZH2 by
ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast
cancer. Sci Rep. 2016 Apr 29;6:24893. doi: 10.1038/srep24893. PubMed PMID:
27128979; PubMed Central PMCID: PMC4850860.


2: Song X, Gao T, Wang N, Feng Q, You X, Ye T, Lei Q, Zhu Y, Xiong M, Xia Y, Yang
F, Shi Y, Wei Y, Zhang L, Yu L. Selective inhibition of EZH2 by ZLD1039 blocks
H3K27 methylation and leads to potent anti-tumor activity in breast cancer. Sci
Rep. 2016 Feb 12;6:20864. doi: 10.1038/srep20864. PubMed PMID: 26868841; PubMed
Central PMCID: PMC4751454.